Certara (NASDAQ:CERT) Issues FY24 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY24 earnings guidance on Wednesday. The company provided EPS guidance of $0.41-0.44 for the period, compared to the consensus EPS estimate of $0.41. The company issued revenue guidance of $380-385 million, compared to the consensus revenue estimate of $386.66 million. Certara also updated its FY 2024 guidance to 0.410-0.440 EPS.

Certara Stock Performance

Shares of CERT stock traded up $0.04 during trading on Friday, reaching $11.03. The company had a trading volume of 1,081,810 shares, compared to its average volume of 786,430. The firm’s 50 day simple moving average is $11.02 and its two-hundred day simple moving average is $13.70. Certara has a one year low of $9.99 and a one year high of $19.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61. The company has a market capitalization of $1.77 billion, a PE ratio of -22.06, a PEG ratio of 4.88 and a beta of 1.51.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The company had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.06 earnings per share. Sell-side analysts forecast that Certara will post 0.27 earnings per share for the current year.

Analysts Set New Price Targets

CERT has been the topic of a number of recent analyst reports. UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Friday, September 27th. Robert W. Baird cut their price target on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday. Finally, Barclays reduced their price objective on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $15.92.

Insider Transactions at Certara

In related news, insider Patrick F. Smith sold 5,409 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares in the company, valued at $552,503.73. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the sale, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.39% of the stock is owned by insiders.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.